Altre lingue Sino Biopharmaceutical Limited

Azioni

1177

KYG8167W1380

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:35 19/04/2024			Variaz. 5gg	Var. 1 gen.
2,34 ^HKD	-3,70%		-14,29%	-32,56%

08/04	Il fiduciario di Sino Biopharmaceutical riacquista azioni	MT
08/04	Sino Biopharmaceutical svilupperà i trattamenti antitumorali di Boehringer Ingelheim in Cina	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	19/04
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	17/04
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	11/04
Sino Biopharmaceutical Trustee Repurchases Shares	08/04
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	08/04
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	08/04
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	29/03
Sino Biopharm (1177.HK) Announces 2023 Annual Results	29/03
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	28/03
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	25/03
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	24/03
Sino Biopharmaceutical's Developing Two Drugs for MASH	15/03
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	15/03
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR	14/03
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet	13/03
Hong Kong Shares Slump Amid Chinese Growth Concerns	05/03
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart	28/02
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China	07/02
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company	07/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sino Biopharmaceutical Limited

Azioni

1177

KYG8167W1380

Altre lingue

Filtri